S&P 500
7,614.00
-0.11%
Dow Jones
51,326.00
-0.09%
Nasdaq 100
30,630.60
-0.28%
Russell 2000
2,927.38
-0.19%
FTSE 100
10,382.60
-0.05%
Nikkei 225
68,184.20
+1.01%

Investing

BioSante’s Cancer Drug Shows Significant Gain (BPAX)

Photo of Paul Ausick
By Paul Ausick Published

Drug maker BioSante Pharmaceuticals Inc. (NASDAQ: BPAX) has released the results of a Phase Ib study of its pancreatic cancer vaccine GVAX indicating that, when used in combination with another drug, patients survive longer. The drug combination “increased the median survival of pancreatic cancer patients with previously treated, locally advanced or metastatic pancreatic adenocarcinoma survival rate” by 60%, from 3.3 months to 5.5 months. The study also showed a jump in one-year survival from 7% to 27%.

In the pre-market this morning, BioSante shares are up about 25% at $0.86.

Follow 24/7 Wall St. on Google
Photo of Paul Ausick
About the Author Paul Ausick →

Paul Ausick has been writing for 247Wallst.com for more than a decade. He has written extensively on investing in the energy, defense, and technology sectors. In a previous life, he wrote technical documentation and managed a marketing communications group in Silicon Valley.

He has a bachelor's degree in English from the University of Chicago and now lives in Montana, where he fishes for trout in the summer and stays inside during the winter.

Continue Reading

Jon C. Ogg |

Merrimack Pharma Wins FDA Approval of Metastatic Pancreatic Cancer Drug

Merrimack Pharmaceuticals saw its shares halted for "news pending" due to an approval from the FDA.

Merrimack Pharma Rises on Positive Late-Stage Results
Chris Lange |

Merrimack Pharma Rises on Positive Late-Stage Results

Merrimack Pharmaceuticals shares saw a handy gain early Tuesday after the company announced positive results for its late stage metastatic…

Jon C. Ogg |

Halozyme Gets New Hope for Shareholders, and for Pancreatic Cancer Patients

Halozyme Therapeutics saw its stock surge on Thursday on news reports that the FDA has removed its clinical hold on…

Is This the Beginning of the End of Aduro BioTech?
Chris Lange |

Is This the Beginning of the End of Aduro BioTech?

Aduro BioTech has announced that the Phase 2b ECLIPSE trial did not meet the primary endpoint of an improvement in…

Merck’s Pancreatic Cancer Treatment Gets FDA Nod
Chris Lange |

Merck’s Pancreatic Cancer Treatment Gets FDA Nod

Merck shares were up handily on Tuesday after the company announced a key update from the FDA on its Lynparza…

Trey Thoelcke |

Three Companies That Want to Cure Pancreatic Cancer

A new research report from Cowen cautions that progress on a cure for pancreatic cancer is slow, but steady. Drugs…

Douglas A. McIntyre |

Select Positive ASCO Data (ARRY, AZN, LLY, DNA, GSK, ONXX, PFE, ZGEN)

Last night was a novel release from the American Society of Clinical Oncology (or ASCO) as the society decided to…

Why NewLink Genetics Shares Hit an All-Time Low
Chris Lange |

Why NewLink Genetics Shares Hit an All-Time Low

NewLink Genetics shares hit an all-time low in Monday’s session after the company provided an update on its brain tumor…

Why Threshold Pharma Is Imploding
Chris Lange |

Why Threshold Pharma Is Imploding

Threshold Pharmaceuticals watched its stock completely collapse in Monday’s session after a joint late-stage study failed to yield positive results.

Top Gaining Stocks

Hewlett Packard Enterprise
HPE • Vol: 153,197,465
Enphase Energy
ENPH • Vol: 8,360,053
Corning
GLW • Vol: 18,152,646
Alexandria Real Estate Equities
ARE • Vol: 4,337,015
Aptiv
APTV • Vol: 6,761,325

Top Losing Stocks

Trade Desk
TTD • Vol: 21,905,513
Intuit
INTU • Vol: 7,383,018
Coterra Energy
CTRA • Vol: 73,319,495
Cboe Global Markets
CBOE • Vol: 5,000,011
HP
HPQ • Vol: 29,259,826